<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791920</url>
  </required_header>
  <id_info>
    <org_study_id>HG-11-01</org_study_id>
    <nct_id>NCT01791920</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines</brief_title>
  <official_title>Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of &quot;Botulax®&quot; Compared to Botox Inj. in Patients With Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of Botulax® with Botox® in the improvement of moderate to
      severe glabellar lines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rate of improvement in glabellar lines with Physician's rating of line severity</measure>
    <time_frame>at 4 weeks post-injection</time_frame>
    <description>Improvement rate of glabellar lines at maximum frown with Physician's rating of lines severity at 4weeks post injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation in experimental drug treatment group</measure>
    <time_frame>4, 8, 12, 16 weeks post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines with Physician's rating of line severity</measure>
    <time_frame>8, 12, 16 weeks post-injection</time_frame>
    <description>Improvement rate of glabellar lines at maximum frown with Physician's rating of lines severity at 8, 12, 16weeks post injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines at rest with investigator's live assessment of severity</measure>
    <time_frame>4, 8, 12, 16 weeks post-injection</time_frame>
    <description>Improvement rate of glabellar lines at rest with investigator's live assessment of severity at 4, 8, 12, 16weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines at maximum frown with investigator's photo assessment</measure>
    <time_frame>4, 8, 12, 16 weeks post-injection</time_frame>
    <description>Improvement rate of glabellar lines at maximum frown with investigator's photo assessment at 4, 8, 12, 16weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines at rest with investigator's photo assessment</measure>
    <time_frame>4, 8, 12, 16 weeks post inejection</time_frame>
    <description>Improvement rate of glabellar lines at rest with investigator's photo assessment at 4, 8, 12, 16weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines with Subject's improvement assessment</measure>
    <time_frame>4, 8, 12, 16 weeks post-injections</time_frame>
    <description>Improvement rate of glabellar lines with Subject's improvement assessment at 4, 8, 12, 16weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's satisfaction rate</measure>
    <time_frame>4, 8, 12, 16 weeks post-injection</time_frame>
    <description>Subject's satisfaction rate of improvement in glabellar lines at 4, 8, 12, 16 weeks post injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Skin Aging</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A(Botulax®)</intervention_name>
    <description>Single administration, Day 0, 20 units</description>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A(Botox®)</intervention_name>
    <description>Single administration, Day 0, 20units</description>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 65

          -  Patients attaining grade 2 or 3 in the investigator's rating of glabellar lines
             severity at maximum frown

          -  Patients who voluntarily sign the informed consent

          -  Patients who can comply with the study procedures and visit schedule

        Exclusion Criteria:

          -  Subjects who had facial plastic surgery (tissue augmentation, brow lift, and dermal
             resurfacing)treatment within 6 months. Those who had peeling or laser therapy

          -  Subjects with skin disorders, scar or infection around glabellar region

          -  Subjects who are taking Aspirin, NSAIDS or anti-coagulant

          -  Subjects with facial palsy or eyelid ptosis

          -  Subjects who diagnosed as neuromuscular junction disorder (e.g., myasthenia gravis,
             Lambert-Eaton Syndrome)

          -  Subjects with history of drug intoxication, alcohol abuse and/or depressive disorder

          -  Subjects with severe internal diseases (cardiovascular, respiratory, renal disease,
             liver disorder)

          -  Subjects who have previously been treated with botulinum toxin within 3 months
             (Botulinum toxin type A: 3months, type B: 4 months)

          -  Subject who have administered following drugs within the previous 4 months:
             Spectinomycin Hydrochloride, Aminoglycoside antibiotics, polypeptide antibiotics,
             tetracycline antibiotics, lincomycin antibiotics, muscle relaxants, anti-cholinergic
             agents, benzodiazepine and similar drugs, benzamide drugs, Tubocurarine-type muscle
             relaxants

          -  Subjects who have possibility to take the drugs listed above

          -  Subjects who have a plan to receive facial cosmetic procedures including dermal
             filler, chemical peeling and dermabrasion during study period

          -  Subjects who have glabellar lines that are unable to be improved with any physical
             method

          -  Subjects who have history of hypersensitivity to Botulinum toxin and other agents

          -  Subjects who are pregnant or breast-feeding

          -  Subjects who have a plan to be pregnant in 3months, or who are not doing contraceptive

          -  Subjects who participated in other studies within 30 days or were not passed over 5
             times of half life for investigational product

          -  Subjects who are having trouble with acute disease

          -  Subjects who have taken any treatment that can affect to glabellar lines and/or any
             lines around forehead within the previous 6 months

          -  Subjects who are unable to communicate or follow the instructions

          -  Subjects who are not eligible for this study based on investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ang University Hopspital</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Jung-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Nowon-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The catholic university of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seongbuk-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

